Creating products that selectively target and treat human disease

Establishing a pipeline of therapeutics companies with a proprietary technology to target inflammation.

About Ashvattha Therapeutics

Ashvattha Therapeutics holds the exclusive rights to a novel hydroxyl dendrimer technology developed at Johns Hopkins University enabling a new class of targeted therapies previously unachievable with traditional drug moieties. Ashvattha are commercializing the technology through new entities established to develop therapeutic opportunities within specific fields and enabled through the use of our dendrimer platform.

OP-101 for COVID-19 Hyperinflammation

OP-101 selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.

Latest News

Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation

June 10, 2020
Orpheris, a subsidiary of Ashvattha, announced results from a Phase 1 single administration study evaluating the subcutaneous (SC) formulation of OP-101 (4 or 8 mg/kg) in healthy volunteers....

Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients

May 28, 2020
Orpheris, a subsidiary of Ashvattha, announced the FDA has agreed to a Phase 2 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of OP-101 in patients with severe COVID-19...

Ashvattha Therapeutics to Present at 2020 AACR Virtual Annual Meeting

May 18, 2020
Ashvattha Therapeutic has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June, 2020....